{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:29:28Z","timestamp":1782844168068,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,3,10]],"date-time":"2006-03-10T00:00:00Z","timestamp":1141948800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Dermatol"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Vitiligo is an acquired depigmenting disorder due to destruction of melanocytes. Although many theories have been suggested for its pathogenesis, the role of autoimmunity is the most popular one. The association of vitiligo with autoimmune thyroid diseases and the increased prevalence of autoantibodies including thyroid autoantibodies in vitiligo favor this role. Our objective was to compare the frequency of thyroid peroxidase antibody (anti-TPO) in vitiligo patients with healthy subjects in Iran.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Ninety-four cases of vitiligo (46 female and 48 male) and 96 control subjects (49 female and 47 male) were enrolled in this controlled study. Patients with known thyroid disease, history of thyroid surgery and those receiving thyroid medications were not included. The two groups were matched regarding gender and age. The demographic data, symptoms related to thyroid diseases and results of skin and thyroid examinations were recorded in a questionnaire for each subject. Thyroid function tests including free T3, free T4 and TSH-IRMA were performed. Anti-TPO levels were assessed as well. The collected data were analyzed by SPSS version-11 in vitiligo patients and subgroups according to gender, age, extent, and duration of the disease compared with the control group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Anti-TPO was detected in 17 (18.1%) of patients affected by vitiligo, while this figure was 7 (7.3%) in the control group; the difference was significant with p-value &lt; 0.025 (Phi &amp; Cramer's V = 0.162). When analyzing subgroups, the difference in the frequency of anti-TPO remained significant only in females (p-value &lt; 0.044) (Phi &amp; Cramer's V = 0.207) and in patients in the age ranges of 18\u201325 (p-value &lt; 0.05) (Phi &amp; Cramer's V = 0.28) and 26\u201335 year-old (p-value &lt; 0.042) (Phi &amp; Cramer's V = 0.304).<\/jats:p><jats:p>The difference of the frequency of anti-TPO was not significant regarding the duration and extent of vitiligo. In addition, there was no significant difference in the levels of free T3, free T4, and TSH in vitiligo patients compared with the control group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>According to our study, anti-TPO was shown to be significantly more common in vitiligo patients especially in young women, compared with control group. As this antibody is a relatively sensitive and specific marker of autoimmune thyroid disorders including Hashimoto thyroiditis and Graves' disease, and considering the fact that vitiligo usually precedes the onset of thyroid dysfunction, periodic follow-up of vitiligo patients for detecting thyroid diseases is further emphasized especially in young women with increased level of anti-TPO.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1471-5945-6-3","type":"journal-article","created":{"date-parts":[[2006,3,10]],"date-time":"2006-03-10T19:20:51Z","timestamp":1142018451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Anti-thyroid peroxidase antibody and vitiligo: a controlled study"],"prefix":"10.1186","volume":"6","author":[{"given":"Maryam","family":"Daneshpazhooh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahtab","family":"Mostofizadeh G","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Behjati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Akhyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza Mahmoud","family":"Robati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,3,10]]},"reference":[{"key":"63_CR1","first-page":"53","volume-title":"Rook's textbook of dermatology","author":"SS Bleehen","year":"2004","unstructured":"Bleehen SS: Disorders of skin color. In Rook's textbook of dermatology. Volume 39. 7th edition. Edited by: Burns T, Breathnach S, Cox N, Griffiths C. Oxford, Blackwell Science; 2004:53\u20137.","edition":"7"},{"key":"63_CR2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2340\/0001555574124128","volume":"74","author":"L Hegedus","year":"1994","unstructured":"Hegedus L, Heidenheim M, Gervil M, Hjalgrim H, Hoier-Madsen M: High frequency of thyroid dysfunction in patients with vitiligo. Acta Derm Venereol 1994, 74: 120\u20133.","journal-title":"Acta Derm Venereol"},{"key":"63_CR3","first-page":"89","volume":"3","author":"YK Shong","year":"1991","unstructured":"Shong YK, Kim JA: Vitiligo in autoimmune thyroid disease. Thyroidology 1991, 3: 89\u201391.","journal-title":"Thyroidology"},{"key":"63_CR4","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/archderm.1983.01650280028010","volume":"119","author":"PE Grimes","year":"1983","unstructured":"Grimes PE, Halder RM, Jones C, Chakrabarti SG, Enterline J, Minus HR, Kenney JA Jr: Autoantibodies and their clinical significance in a black vitiligo population. Arch Dermatol 1983, 119: 300\u20133. 10.1001\/archderm.119.4.300","journal-title":"Arch Dermatol"},{"key":"63_CR5","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1067\/mjd.2003.257","volume":"48","author":"J Ai","year":"2003","unstructured":"Ai J, Leonhardt MJ, Heymann RW: Autoimmune thyroid diseases. Etiology, Pathogenesis, and dermatologic manifestations. J Am Acad Dermatol 2003, 48: 641\u201359. 10.1067\/mjd.2003.257","journal-title":"J Am Acad Dermatol"},{"key":"63_CR6","volume-title":"Werner and Ingbar's the Thyroid: A Fundamental and Clinical Text","author":"L Braverman","year":"2005","unstructured":"Braverman L, Uitger RD, (eds): Werner and Ingbar's the Thyroid: A Fundamental and Clinical Text. 9th edition. NewYork, Lippincott Williams and Wilkins; 2005:363.","edition":"9"},{"key":"63_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1034\/j.1600-0749.2003.00032.x","volume":"16","author":"A Alkhateeb","year":"2003","unstructured":"Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA: Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 2003, 16: 208\u201314. 10.1034\/j.1600-0749.2003.00032.x","journal-title":"Pigment Cell Res"},{"key":"63_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/08916930410001710857","volume":"37","author":"EH Kemp","year":"2004","unstructured":"Kemp EH: Autoantibodies as diagnostic and predictive markers of vitiligo. Autoimmunity 2004, 37: 287\u201390. 10.1080\/08916930410001710857","journal-title":"Autoimmunity"},{"key":"63_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1365-4362.1996.tb01609.x","volume":"35","author":"RC Mandry","year":"1996","unstructured":"Mandry RC, Ortiz LJ, Lugo-Somolinos A, Sanchez JL: Organ-specific autoantibodies in vitiligo patients and their relatives. Int J Dermatol 1996, 35: 18\u201321.","journal-title":"Int J Dermatol"},{"key":"63_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000081479","volume":"210","author":"P Iacovelli","year":"2005","unstructured":"Iacovelli P, Sinagra JL, Vidolin AP, Marenda S, Capitanio B, Leone G, Picardo M: Relevance of thyroiditis and of other autoimmune diseases in children with vitiligo. Dermatology 2005, 210: 26\u201330. 10.1159\/000081479","journal-title":"Dermatology"},{"key":"63_CR11","first-page":"139","volume":"14","author":"M Morgan","year":"1986","unstructured":"Morgan M, Castells A, Ramirez A: Autoantibodies in vitiligo: clinical significance. Med Cutan Ibero Lat Am 1986, 14: 139\u201342.","journal-title":"Med Cutan Ibero Lat Am"},{"key":"63_CR12","first-page":"68","volume":"48","author":"S Dave","year":"2003","unstructured":"Dave S, D'Souza M, Thappa DM, Reddy KS, Bobby Z: High frequency of thyroid dysfunction in Indian patients with vitiligo. Indian J Dermatol 2003, 48: 68\u201372.","journal-title":"Indian J Dermatol"},{"key":"63_CR13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1159\/000249466","volume":"171","author":"C Betterle","year":"1985","unstructured":"Betterle C, Caretto A, De Zio A, Pedini B, Veller-Fornasa C, Cecchetto A, Accordi F, Peserico A: Incidence and significance of organ-specific autoimmune disorders (clinical, latent or only autoantibodies) in patients with vitiligo. Dermatologica 1985, 171: 419\u201323.","journal-title":"Dermatologica"},{"key":"63_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/j.1600-0560.1984.tb00413.x","volume":"11","author":"W Korkij","year":"1984","unstructured":"Korkij W, Soltani K, Simjee S, Marcincin PG, Chuang TY: Tissue-specific autoantibodies and autoimmune disorders in vitiligo and alopecia areata: a retrospective study. J Cutan Pathol 1984, 11: 522\u201330.","journal-title":"J Cutan Pathol"},{"key":"63_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1468-3083.2004.00728.x","volume":"18","author":"A Kurtev","year":"2004","unstructured":"Kurtev A, Dourmishev AL: Thyroid function and autoimmunity in children and adolescents with vitiligo. J Eur Acad Dermatol Venereol 2004, 18: 109\u201311. 10.1111\/j.1468-3083.2004.00728.x","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["BMC Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-5945-6-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-5945-6-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-5945-6-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-5945-6-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T08:06:27Z","timestamp":1706947587000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcdermatol.biomedcentral.com\/articles\/10.1186\/1471-5945-6-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,10]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["63"],"URL":"https:\/\/doi.org\/10.1186\/1471-5945-6-3","relation":{},"ISSN":["1471-5945"],"issn-type":[{"value":"1471-5945","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,10]]},"assertion":[{"value":"24 June 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"3"}}